Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

ClinicalTrials.gov ID: NCT00838201

Public ClinicalTrials.gov record NCT00838201. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

Study identification

NCT ID: NCT00838201
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Amgen; Industry
Enrollment: 384 participants

Conditions and interventions

Conditions

Interventions

Denosumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 31, 2009
Primary completion: May 2, 2012
Completion: May 2, 2012
Last update posted: Oct 17, 2018

2009 – 2012

United States locations

U.S. sites: 27
U.S. states: 15
U.S. cities: 26

Facility	City	State	ZIP	Site status
Research Site	Huntsville	Alabama	35801	—
Research Site	Anaheim	California	92801	—
Research Site	Laguna Hills	California	92653	—
Research Site	Long Beach	California	90813	—
Research Site	San Bernardino	California	92404	—
Research Site	San Diego	California	92103	—
Research Site	San Diego	California	92120	—
Research Site	Santa Monica	California	90404	—
Research Site	Middlebury	Connecticut	06762	—
Research Site	New Britain	Connecticut	06052	—
Research Site	Trinity	Florida	34655	—
Research Site	Fort Wayne	Indiana	46825	—
Research Site	Greenbelt	Maryland	20770	—
Research Site	Sartell	Minnesota	56377	—
Research Site	Omaha	Nebraska	68114	—
Research Site	Albany	New York	12208	—
Research Site	Bay Shore	New York	11706	—
Research Site	Garden City	New York	11530	—
Research Site	Poughkeepsie	New York	12601	—
Research Site	Lancaster	Pennsylvania	17604	—
Research Site	East Providence	Rhode Island	02914	—
Research Site	Myrtle Beach	South Carolina	29572	—
Research Site	Dallas	Texas	75231	—
Research Site	Salem	Virginia	24153	—
Research Site	Burien	Washington	98166	—
Research Site	Seattle	Washington	98104	—
Research Site	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00838201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 17, 2018 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00838201 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →